Walleye Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Walleye Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-80,047	Closed	-$1.36K	–	1578
2020 Q4	$1.36K	Buy	+80,047	New	+$1M	0.09%	190
2020 Q1	–	Sell	-49,258	Closed	-$226K	–	1981
2019 Q4	$226K	Buy	+49,258	New	+$195K	0.01%	1050
2019 Q3	–	Sell	-47,500	Closed	-$286K	–	2413
2019 Q2	$286K	Buy	+47,500	New	+$454K	0.03%	758

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Walleye Capital's FPRX Position: Q1 2021 in Review

Walleye Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 80,047 shares — an estimated $1.36K sold.

Walleye Capital first reported a position in FPRX in Q2 2019 and held it in 3 quarters. The position peaked at $286K in Q2 2019. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Walleye Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Walleye Capital sold 80,047 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $1.36K.
Walleye Capital first reported a position in Five Prime Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
Walleye Capital's Five Prime Therapeutics, Inc. position peaked at $286K in Q2 2019.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Walleye Capital's 13F filing for Q1 2021, filed 17 May 2021.